



MASSACHUSETTS

Blue Cross Blue Shield of Massachusetts is an Independent Licensee of the Blue Cross and Blue Shield Association

Medical Policy

Dopamine Transporter Imaging with Single Photon Emission Computed Tomography

Table of Contents

- [Policy: Commercial](#)
- [Policy: Medicare](#)
- [Authorization Information](#)
- [Coding Information](#)
- [Description](#)
- [Policy History](#)
- [Information Pertaining to All Policies](#)
- [References](#)

Policy Number: 918

BCBSA Reference Number: 6.01.54

NCD/LCD: NA

Related Policies

Deep Brain Stimulation, #[473](#)

Positron Emission Tomography (PET) Brain Imaging, #[903](#)

Policy

Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity Medicare HMO BlueSM and Medicare PPO BlueSM Members

Dopamine transporter imaging with single-photon emission computed tomography may be considered **MEDICALLY NECESSARY** when used for individuals with:

- clinically uncertain Parkinson disease; or
- clinically uncertain dementia with Lewy bodies.

Use of dopamine transporter imaging with single-photon emission computed tomography is considered **INVESTIGATIONAL** for all other indications not included above.

Prior Authorization Information

Inpatient

- For services described in this policy, precertification/preauthorization **IS REQUIRED** for all products if the procedure is performed **inpatient**.

Outpatient

- For services described in this policy, see below for products where prior authorization **might be required** if the procedure is performed **outpatient**.

	Outpatient
Commercial Managed Care (HMO and POS)	Prior authorization is not required .
Commercial PPO and Indemnity	Prior authorization is not required .
Medicare HMO Blue SM	Prior authorization is not required .

Medicare PPO Blue SM	Prior authorization is not required .
---------------------------------	--

CPT Codes / HCPCS Codes / ICD Codes

Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.

Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.

The following codes are included below for informational purposes only; this is not an all-inclusive list.

The above **medical necessity criteria MUST** be met for the following codes to be covered for Commercial Members: Managed Care (HMO and POS), PPO, Indemnity, Medicare HMO Blue and Medicare PPO Blue:

CPT Codes

CPT codes:	Code Description
78607	Brain imaging, tomographic (SPECT)

HCPCS Codes

HCPCS codes:	Code Description
A9584	Iodine I-123 ioflupane, diagnostic, per study dose, up to 5 millicuries

The following ICD Diagnosis Codes are considered medically necessary when submitted with the HCPCS code above if **medical necessity criteria** are met:

ICD-10 Diagnosis Coding

ICD-10-CM-diagnosis codes:	Code Description
F02.80	Dementia in other diseases classified elsewhere without behavioral disturbance
F02.81	Dementia in other diseases classified elsewhere with behavioral disturbance
G20	Parkinson's disease
G21.9	Secondary parkinsonism, unspecified
G31.83	Dementia with Lewy bodies
R25.0	Abnormal head movements
R25.1	Tremor, unspecified
R25.8	Other abnormal involuntary movements
R25.9	Unspecified abnormal involuntary movements
R26.0	Ataxic gait
R26.2	Difficulty in walking, not elsewhere classified
R26.89	Other abnormalities of gait and mobility
R26.9	Unspecified abnormalities of gait and mobility
R41.89	Other symptoms and signs involving cognitive functions and awareness
R41.9	Unspecified symptoms and signs involving cognitive functions and awareness

Description

PARKINSON DISEASE

Parkinsonian syndromes are a group of diseases that share similar cardinal signs, characterized by bradykinesia, rigidity, resting tremor, and gait disturbance. Parkinson disease (PD) is the most common cause of parkinsonism.

Diagnosis

Despite the well-known symptoms of PD, diagnosis is challenging even for experienced clinicians, particularly in early stages of the disease. In addition, other etiologies such as essential tremor, corticobasal degeneration, multiple system atrophy, progressive supranuclear palsy, vascular parkinsonism, and drug-induced parkinsonism can lead to a similar set of symptoms.

While the criterion standard is postmortem histopathology, clinical diagnosis may be used as an interim reference standard. The accuracy of the diagnosis is influenced by the duration of the symptoms and the clinician's experience.¹ Even in specialized movement disorders centers, up to 25% of patients may be misclassified, and some patients (eg, those with essential tremor who have been diagnosed with PD) may be erroneously treated.² Such misclassifications have led to the call for additional diagnostic tests and biomarkers to improve the accuracy of clinical diagnosis of PD and other parkinsonian syndromes. One recent approach is to evaluate the integrity of dopaminergic pathways in the brain using dopamine transporter imaging with single-photon emission computed tomography (DaT-SPECT) imaging.

DEMENTIA WITH LEWY BODIES

Dementia with Lewy bodies (DLB) is a type of dementia characterized by parkinsonism, visual hallucinations, cognitive fluctuation, sleep disorders, and severe neuroleptic sensitivity. DLB is the second most common form of degenerative dementia; Alzheimer disease, which can have similar symptoms at onset, is the most common.

Diagnosis

Diagnosis can be challenging, particularly when patients have multiple comorbidities including cerebrovascular disease and/or Alzheimer disease.³ As with PD, DLB is characterized by the degeneration of nigrostriatal neurons; as such, DaT-SPECT is also proposed to differentiate DLB from Alzheimer disease. Misdiagnosis of DLB is concerning because some have noted a severe sensitivity (potentially life-threatening) to neuroleptics in patients with DLB. However, newer agents are usually well-tolerated, and patients with DLB may also respond to the cholinesterase inhibitors that are more commonly used to treat Alzheimer disease.

DAT-SPECT

DaT-SPECT is based on the selective affinity of DaT ligands for dopamine-synthesizing neurons, which allows visualization of deficits in the nigrostriatal dopaminergic pathway.

DaT ligands include iodine 123I-2β-carbomethoxy-3β-(4-iodophenyl) tropane (¹²³I-β-CIT), which is a cocaine analogue with an affinity for both dopamine and serotonin transporters. Intravenous ¹²³I-β-CIT requires a delay between injection and scan of about 24 hours. Iodine-123 N-(3-fluoropropyl)-2β-carbomethoxy-3β-(4-iodophenyl) nortropane (¹²³I-FP-CIT) is a fluoropropyl derivate of β-CIT that is selective for brain striatal DaT but can also bind to the serotonin transporter. Intravenous ¹²³I-FP-CIT can be injected 3 to 6 hours before the scan (DaTscan). Other SPECT ligands with affinity for dopamine transporter include technetium 99m (2β((N,N'-bis(2-mercaptoethyl) ethylene diamino)methyl) and 3β-(4-chlorophenyl) tropane (^{99m}Tc-TRODAT-1).^{4,5}

Binding of ligands with affinity for DaT ligands in the striatum is, in general, reduced in PD, genetic parkinsonism, DLB, corticobasal degeneration, progressive supranuclear palsy, and multiple system atrophy. In contrast, striatal DaT ligand binding is expected to be within the normal range of Alzheimer disease, essential tremor, dystonic tremor, orthostatic tremor, drug-induced parkinsonism, and psychogenic parkinsonism.⁴

Visualization of striatal dopamine transporter binding, through DaT-SPECT, permits assessment of presynaptic dopaminergic deficit. It is proposed that an abnormal DaT-SPECT scan supports the diagnosis of PD, DLB, or other neurodegenerative parkinsonian syndrome, while a normal DaT-SPECT scan in a symptomatic patient supports the diagnosis of a disease not affecting the nigrostriatal dopaminergic pathway.

Analysis of DaT-SPECT images can be visual, semiquantitative, or quantitative. In patients with PD, physical symptoms start after 30% to 50% of dopaminergic neurons have degenerated.^{6,7} Symptomatic patients with PD would be thus expected to have sufficient abnormality on DaT-SPECT for visual analysis to be adequate for interpretation. A variety of methods are being tested to improve the validity and reliability of ratings, including commercially available software to define the region of interest for analysis and the development of an atlas for visual interpretation. Several research centers are developing quantitative and semiquantitative classification methods for the evaluation of DaT-SPECT images.⁸⁻¹¹

Anatomic variation in the brain, including vascular lesions, may interfere with the distribution of the iodine-123 tracer and could result in an abnormal scan.¹² Dopamine agonists and levodopa may also affect DaT expression, which could influence the ability of DaT-SPECT to monitor the progression of disease unless these agents are discontinued prior to imaging. Patients with clinically diagnosed PD or DLB, who present with a normal DaT-SPECT scan, are referred to in the literature as having “scans without evidence of dopaminergic deficit.” While many of these patients are ultimately diagnosed with non-PD syndromes, a portion of patients with normal DaT-SPECT imaging are confirmed to have PD or DLB by the reference standard. In studies where clinical diagnosis is used as an end point, scans without evidence of dopaminergic deficit are present in 3% to 20% of PD patients.¹³ In a study of patients clinically diagnosed with DLB, van der Zande et al (2016) found that 10% of these patients had normal scans.¹⁴ Further research may shed light on these cases.

Summary

Dopamine transporter imaging with single-photon emission computed tomography (DaT-SPECT), using radiopharmaceutical ioflupane (¹²³I) injection, is a neuroimaging modality being evaluated to improve the differential diagnosis of parkinsonian syndromes from nonparkinsonian tremor, as well as dementia with Lewy bodies from Alzheimer disease.

The following conclusions are based on a view of the evidence, including, but not limited to, published evidence and clinical expert opinion, via BCBSA’s Clinical Input Process.

For individuals who have clinically uncertain Parkinson disease who receive DaT-SPECT, the published evidence includes randomized controlled trials, cohort studies, and case series studies. Relevant outcomes are symptoms, functional outcomes, and treatment-related mortality and morbidity. In populations with clinically apparent Parkinson disease, studies of diagnostic accuracy have reported high sensitivity and specificity for Parkinson disease. Studies of clinical validity in the target population of clinically uncertain Parkinson disease are limited by gaps in study design, conduct, and relevance. Evidence on clinical utility in the target population includes a randomized controlled trial showing no significant difference in outcomes over time between patients who received a DaT-SPECT scan and those who did not. Evidence reported through clinical input augments the published evidence by highlighting that the published randomized controlled trial also reported changes in management following DaT-SPECT imaging that may translate to improvements in health outcomes over time, and the 1-year study follow-up may be too short to demonstrate significant improvement in quality of life in a slowly progressive disease such as Parkinson disease. Clinical input further supports that DaT-SPECT offers clinically valid diagnostic information about the presence or absence of functional loss in the dopamine system (ie, nigrostriatal degeneration) and is clinically useful for clinically uncertain Parkinson syndrome when a negative result on DaT-SPECT is used to inform treatment decisions by reducing or avoiding unnecessary dopaminergic therapy. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have clinically uncertain dementia with Lewy bodies who receive DaT-SPECT, the published evidence includes randomized control trials, cohort studies, and case series studies. Relevant outcomes are symptoms, functional outcomes, and treatment-related mortality and morbidity. No such studies have been performed in the target population of clinically uncertain dementia with Lewy bodies. No studies have directly evaluated the effect of DaT-SPECT on health outcomes in the target population. Evidence reported through clinical input augments the published evidence by supporting that DaT-SPECT offers clinically valid diagnostic information about the presence or absence of functional loss in the dopamine system (ie, nigrostriatal degeneration) and is clinically useful for clinically uncertain DLB using

a chain of evidence where a positive result on DaT-SPECT is used to inform treatment decisions by avoiding potentially harmful use of neuroleptics typically used in dementia patients. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

Thus, the above indications may be considered medically necessary considering the suggestive evidence including clinical input support.

Policy History

Date	Action
4/2019	BCBSA National medical policy review. New medically necessary indications described for clinically uncertain Parkinson disease and clinically uncertain dementia with Lewy bodies. Clarified coding information. Effective 4/1/2019.
11/2017	New references added from BCBSA National medical policy.
10/2016	New references added from BCBSA National medical policy.
1/2016	New references added from BCBSA National medical policy.
12/2015	Added coding information.
9/2014	New references added from BCBSA National medical policy.
10/2013	New references from BCBSA National medical policy.
2/2013	New policy describing non-coverage.

Information Pertaining to All Blue Cross Blue Shield Medical Policies

Click on any of the following terms to access the relevant information:

[Medical Policy Terms of Use](#)

[Managed Care Guidelines](#)

[Indemnity/PPO Guidelines](#)

[Clinical Exception Process](#)

[Medical Technology Assessment Guidelines](#)

References

1. Rizzo G, Copetti M, Arcuti S, et al. Accuracy of clinical diagnosis of Parkinson disease: A systematic review and meta-analysis. *Neurology*. Feb 09 2016;86(6):566-576. PMID 26764028
2. Scherfler C, Schwarz J, Antonini A, et al. Role of DAT-SPECT in the diagnostic work up of parkinsonism. *Mov Disord*. Jul 15 2007;22(9):1229-1238. PMID 17486648
3. Elahi FM, Miller BL. A clinicopathological approach to the diagnosis of dementia. *Nat Rev Neurol*. Aug 2017;13(8):457-476. PMID 28708131
4. Kagi G, Bhatia KP, Tolosa E. The role of DAT-SPECT in movement disorders. *J Neurol Neurosurg Psychiatry*. Jan 2010;81(1):5-12. PMID 20019219
5. Levine CB, Fahrback KR, Siderowf AD, et al. *Diagnosis and Treatment of Parkinson's Disease: A Systematic Review of the Literature (Evidence Report/Technology Assessment No. 57)*. Rockville, MD: Agency for Healthcare Research and Quality; 2003.
6. Burke RE, O'Malley K. Axon degeneration in Parkinson's disease. *Exp Neurol*. Aug 2013;246:72-83. PMID 22285449
7. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. *N Engl J Med*. Dec 9 2004;351(24):2498-2508. PMID 15590952
8. Prashanth R, Roy SD, Mandal PK, et al. High-accuracy classification of parkinson's disease through shape analysis and surface fitting in 123I-ioflupane SPECT imaging. *IEEE J Biomed Health Inform*. May 2017;21(3):794-802. PMID 28113827
9. Skanjeti A, Castellano G, Elia BO, et al. Multicenter semiquantitative evaluation of (123)I-FP-CIT brain SPECT. *J Neuroimaging*. Nov-Dec 2015;25(6):1023-1029. PMID 25923060
10. Ueda J, Yoshimura H, Shimizu K, et al. Combined visual and semi-quantitative assessment of 123I-FP-CIT SPECT for the diagnosis of dopaminergic neurodegenerative diseases. *Neurol Sci*. Jul 2017;38(7):1187-1191. PMID 28389938
11. Booi J, Dubroff J, Pryma D, et al. Diagnostic performance of the visual reading of 123I-ioflupane SPECT images when assessed with or without quantification in patients with movement disorders or dementia. *J Nucl Med*. Nov 2017;58(11):1821-1826. PMID 28473597

12. Nuvoli S, Spanu A, Piras MR, et al. 123I-ioflupane brain SPECT and 123I-MIBG cardiac planar scintigraphy combined use in uncertain parkinsonian disorders. *Medicine (Baltimore)*. May 2017;96(21):e6967. PMID 28538394
13. Erro R, Schneider SA, Stamelou M, et al. What do patients with scans without evidence of dopaminergic deficit (SWEDD) have? New evidence and continuing controversies. *J Neurol Neurosurg Psychiatry*. Mar 2016;87(3):319-323. PMID 25991401
14. van der Zande JJ, Booij J, Scheltens P, et al. [(123)I]FP-CIT SPECT scans initially rated as normal became abnormal over time in patients with probable dementia with Lewy bodies. *Eur J Nucl Med Mol Imaging*. Jun 2016;43(6):1060-1066. PMID 26830298
15. GE Healthcare. DaTscan Ioflupane I123 Injection Full Prescribing Information. n.d.; http://www3.gehealthcare.com/en/products/categories/nuclear_imaging_agents/datscan. Accessed May 10, 2018.
16. Tu XJ, Hwang WJ, Ma HI, et al. Determinants of generic and specific health-related quality of life in patients with Parkinson's disease. *PLoS One*. Jun 26 2017;12(6):e0178896. PMID 28650957
17. Marshall VL, Reiningger CB, Marquardt M, et al. Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [(123)I]FP-CIT SPECT. *Mov Disord*. Mar 15 2009;24(4):500-508. PMID 19117369
18. Vlaar AM, de Nijs T, Kessels AG, et al. Diagnostic value of 123I-ioflupane and 123I-iodobenzamide SPECT scans in 248 patients with parkinsonian syndromes. *Eur Neurol*. Feb 2008;59(5):258-266. PMID 18264015
19. Kupsch AR, Bajaj N, Weiland F, et al. Impact of DaTscan SPECT imaging on clinical management, diagnosis, confidence of diagnosis, quality of life, health resource use and safety in patients with clinically uncertain parkinsonian syndromes: a prospective 1-year follow-up of an open-label controlled study. *J Neurol Neurosurg Psychiatry*. Jun 2012;83(6):620-628. PMID 22492213
20. Kupsch A, Bajaj N, Weiland F, et al. Changes in clinical management and diagnosis following DaTscan SPECT imaging in patients with clinically uncertain parkinsonian syndromes: a 12-week follow-up study. *Neurodegener Dis*. May 8 2013;11(1):22-32. PMID 22571977
21. Hauser RA, Bajaj N, Marek K, et al. Sensitivity, specificity, positive and negative predictive values and diagnostic accuracy of DaTscan(TM) (Ioflupane I123 injection): Predicting clinical diagnosis in early clinically uncertain parkinsonian syndrome. *J Neurol Stroke*. May 11 2014;1(1):00003.
22. Bajaj N, Hauser RA, Seibyl J, et al. Association between Hoehn and Yahr, Mini-Mental State Examination, age, and clinical syndrome predominance and diagnostic effectiveness of ioflupane I 123 injection (DaTSCAN) in subjects with clinically uncertain parkinsonian syndromes. *Alzheimers Res Ther*. Dec 2014;6(5-8):67. PMID 25478029
23. Brigo F, Matinella A, Erro R, et al. [(1)(2)(3)I]FP-CIT SPECT (DaTSCAN) may be a useful tool to differentiate between Parkinson's disease and vascular or drug-induced parkinsonisms: a meta-analysis. *Eur J Neurol*. Nov 2014;21(11):1369-e1390. PMID 24779862
24. O'Brien JT, Oertel WH, McKeith IG, et al. Is ioflupane I123 injection diagnostically effective in patients with movement disorders and dementia? Pooled analysis of four clinical trials. *BMJ Open*. Jul 03 2014;4(7):e005122. PMID 24993764
25. Sadasivan S, Friedman JH. Experience with DaTscan at a tertiary referral center. *Parkinsonism Relat Disord*. Jan 2015;21(1):42-45. PMID 25465746
26. Oravivattanakul S, Benchaya L, Wu G, et al. Dopamine transporter (DaT) scan utilization in a movement disorder center. *Mov Disord Clin Pract*. Oct 2015;3(1):31-35.
27. Bega D, Gonzalez-Latapi P, Zadikoff C, et al. Is there a role for DAT-SPECT Imaging in a specialty movement disorders practice? *Neurodegener Dis*. Jan 2015;15(2):81-86. PMID 25592727
28. Catafau AM, Tolosa E. Impact of dopamine transporter SPECT using 123I-ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes. *Mov Disord*. Oct 2004;19(10):1175-1182. PMID 15390019
29. Tolosa E, Borghet TV, Moreno E. Accuracy of DaTSCAN (123I-ioflupane) SPECT in diagnosis of patients with clinically uncertain parkinsonism: 2-year follow-up of an open-label study. *Mov Disord*. Dec 2007;22(16):2346-2351. PMID 17914722
30. Galvin JE. Improving the clinical detection of Lewy body dementia with the Lewy Body Composite Risk Score. *Alzheimers Dement (Amst)*. Sep 01 2015;1(3):316-324. PMID 26405688

31. McKeith I, O'Brien J, Walker Z, et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. *Lancet Neurol.* Apr 2007;6(4):305-313. PMID 17362834
32. Walker Z, Moreno E, Thomas A, et al. Clinical usefulness of dopamine transporter SPECT imaging with 123I-FP-CIT in patients with possible dementia with Lewy bodies: randomised study. *Br J Psychiatry.* Feb 2015;206(2):145-152. PMID 25431431
33. Walker Z, Moreno E, Thomas A, et al. Evolution of clinical features in possible DLB depending on FP-CIT SPECT result. *Neurology.* Sep 06 2016;87(10):1045-1051. PMID 27511183
34. Kemp PM, Clyde K, Holmes C. Impact of 123I-FP-CIT (DaTSCAN) SPECT on the diagnosis and management of patients with dementia with Lewy bodies: a retrospective study. *Nucl Med Commun.* Apr 2011;32(4):298-302. PMID 21278615
35. Wippold FJ, 2nd, Brown DC, Broderick DF, et al. ACR Appropriateness Criteria Dementia and Movement Disorders. *J Am Coll Radiol.* Jan 2015;12(1):19-28. PMID 25557568
36. Suchowersky O, Reich S, Perlmutter J, et al. Practice Parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology.* Apr 11 2006;66(7):968-975. PMID 16606907
37. Djang DS, Janssen MJ, Bohnen N, et al. SNM practice guideline for dopamine transporter imaging with 123I-ioflupane SPECT 1.0. *J Nucl Med.* Jan 2012;53(1):154-163. PMID 22159160
38. Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. *Mov Disord.* Oct 2015;30(12):1591-1601. PMID 26474316
39. Berg D, Adler CH, Bloem BR, et al. Movement Disorder Society criteria for clinically established early Parkinson's disease. *Mov Disord.* Oct 2018;33(10):1643-1646. PMID 30145841
40. National Institute for Health and Care Excellence (NICE). Parkinson's disease in over 20s: diagnosis and management [CG35]. 2006; <https://www.nice.org.uk/guidance/cg35#diagnosing-parkinsons-disease>. Accessed May 10, 2018.
41. National Institute for Health and Care Excellence (NICE). Parkinson's disease in adults [NG71]. 2017; <https://www.nice.org.uk/guidance/NG71>. Accessed May 10, 2018.
42. Rogers G, Davies D, Pink J, et al. Parkinson's disease: summary of updated NICE guidance. *BMJ.* Jul 27 2017;358:j1951. PMID 28751362
43. National Institute for Health and Care Excellence (NICE). Dementia: assessment, management and support for people living with dementia and their carers [NG97]. 2018; <https://www.nice.org.uk/guidance/ng97>. Accessed October 28, 2018.
44. McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. *Neurology.* Jul 04 2017;89(1):88-100. PMID 28592453